Radiation Dermatitis Market

• Approximately 95% of patients receiving radiation therapy suffer from some degree of radiodermatitis whereas around 85% of the total patient base experience moderate-to-severe radiodermatitis that requires intensive treatment.
• An acute dermatitis typically occurs within 90 days of exposure. Chronic dermatitis usually occurs after 90 days. Clinical manifestations range from mild erythema resembling a sunburn to chronic ulcerations.
• Of the current therapies for radiodermatitis, the topical product segment has captured the largest share compared to other segments. And this substantial share is presumed to be a consequence of benefits associated with topical products such as easy application, availability, and high cost-efficiency, their benefits are predicted to be some of the major factors fuelling the adoption of tropical products over the previous years.
• Corticosteroids may lead to skin thinning, which in turn could result in skin dehydration. Also, research on aloe vera, hyaluronic acid, corticosteroids sucralfate, in lotions, creams, and emulsions did not consistently demonstrate effectiveness in treating radiation dermatitis.
• Despite initial indications of the effectiveness of silicone-based film dressings, these solid dressings can have drawbacks such as a minor bolus effect.
• At present, there is a lack of uniformity in the prevention and management of skin reactions in radiodermatitis patients, leading to inconsistent clinical care recommendations globally.
• In July 2024, Enveric Biosciences and Aries Science & Technology announced a licensing agreement for the clinical development of Enveric’s patented radiation dermatitis topical product.
• RepoCeuticals has initiated a clinical trial in collaboration with Danish University Hospitals to assess RepoCeutical protective melatonins’ skin cream efficacy in preventing and alleviating radiation dermatitis by application to the breast area or upper torso.
• Emerging Radiation Dermatitis Companies such as Repoceuticals, Xequel Bio, Amryt Pharma, Lutris Pharma, and others are evaluating their candidates for radiation dermatitis.

Request for Unlocking the Sample Page of the "Radiation Dermatitis Treatment Market"

DelveInsight's “Radiation Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of historical and forecasted epidemiology as well as the radiation dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Radiation Dermatitis Treatment Market Report provides current treatment, emerging therapies, market share of individual therapies, and historical and forecasted 7MM radiation dermatitis market size from 2020 to 2034. The report also covers current radiation dermatitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Radiation Dermatitis Treatment Market: Understanding and Algorithm

Radiation dermatitis, also known as radiodermatitis, x-ray dermatitis, radiation skin damage, or radiation burn, is a condition that primarily affects the skin followed by exposure to radiation therapy, it is termed as a side effect of the radiation treatment. Development and severity of radiation dermatitis are associated with multiple patient and treatment factors such as total radiation dose, duration of radiotherapy, and treatment with chemotherapy. Radiation dermatitis occurs especially in patients with skin cancer, breast cancer, head and neck cancer, lung cancer, or sarcoma. It can also occur as an acute inflammatory reaction in response to a systemic drug long after radiotherapy and within days or months following treatment with a triggering agent. 

Radiation Dermatitis Diagnosis

A skin biopsy is usually not necessary for the diagnosis of radiation dermatitis. However, histopathologic examination of a skin biopsy may be helpful if the diagnosis is uncertain. The diagnosis of acute radiation dermatitis is clinical, based upon the finding of skin changes in a patient with a history of radiation therapy in the previous three months. The sharp demarcation of the skin changes and their limitation to the irradiated areas are important clues to the diagnosis. Subjective symptoms, including skin pain and pruritus, should also be assessed. Key elements of history are the duration of treatment and the cumulative dose of radiation.

Further details related to country-based variations in diagnosis are provided in the report…

Radiation Dermatitis Treatment

Treatment involves measures aimed at preventing secondary skin infection and the use of dressings over the areas of skin sloughing. If infection occurs, standard therapy for bacterial infections should be initiated with topical and/or systemic antibiotics. Topical steroid cream is often prescribed for radiation dermatitis, although clinical evidence is mixed concerning this treatment option. A variety of wound dressings are used, including nonadherent, hydrogel, or hydrocolloid dressings (eg, StrataXRT, Mepitel, Mepilex). However, there is little evidence to aid in the choice among the various types of dressings.

Radiation Dermatitis Epidemiology

The radiation dermatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by radiotherapy utilization, incidence of radiation dermatitis, grade-specific cases of radiation dermatitis, treated cases of radiation dermatitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The total incident population of radiation dermatitis in 7MM in the year 2023 was more than 3 million with the US accounting for the maximum number of cases, i.e., 1.3 million followed by Japan.
• In the US, in 2023, breast cancer accounted for the maximum number of cases for radiotherapy utilization, followed by lung cancer and prostate cancer.
• Among EU4, Germany has the highest number of incident cases of radiation dermatitis and Spain has the lowest number of incident cases.
• Moderate radiation dermatitis was more common grade followed by mild and severe. In 2023, the cases of Grade II (moderate dermatitis) in the US were found to be ~640,000.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Radiation Dermatitis Prevalence

Radiation Dermatitis Drug Chapters

The drug chapter segment of the radiation dermatitis therapeutics market report encloses a detailed analysis of radiation dermatitis early and mid-stage (IND, and Phase II) pipeline drugs. It also deep dives into the radiation dermatitis pivotal clinical trial details, recent and expected market approvals, patent details, the latest Radiation Dermatitis news, and recent deals and collaborations. 

Radiation Dermatitis Marketed Drugs 

• StrataXRT: Stratpharma AG

StrataXRT is a semi-occlusive, self-drying, transparent gel. StrataXRT forms a thin protective film on the skin surface to minimize Transepidermal Water Loss (TEWL) to keep the skin hydrated. StrataXRT can be used after the very first radiation session to minimize the development of radiation dermatitis. StrataXRT addresses all stages of radiation dermatitis. 

In July 2017, the company announced the launch of StrataXRT, the first and only topical film-forming wound dressing specifically designed to manage radiation dermatitis. StrataXRT is superior to moisturizer in preventing and reducing severity of skin toxicity and 41% and 49.4% reduction in risk of developing grade 2 and grade 3 skin toxicity. StrataXRT does not need to be removed, which can be traumatic for patients when dressings need to be removed and reapplied.

Get More Insights @ STRATAXRT Market

• XonRID Gel: Venture Life/ Helsinn Healthcare

XonRID is a topical gel used to relieve the symptoms of radiation-induced dermatitis. XonRID prevents and treats skin symptoms such as erythema, itching, burning sensation, and pruritus, induced by radiotherapy or other causes.

In December 2016, it received 510(K) FDA clearance in the US. This now allows Xonrid Gel to be marketed in the US for the management and relief of the burning and itching experienced by patients with radiation dermatitis. XonRID is also classified as a medical device in the EU.

Radiation Dermatitis Emerging Drugs

• Granexin Gel: Xequel Bio 

According to Xequel Bio pipeline, Granexin Gel is in Phase II trial and has demonstrated safety and efficacy in multiple preclinical and clinical studies. This topical treatment has been evaluated in six clinical trials for the treatment of acute and chronic wounds. It has shown wound healing acceleration, slowed injury progress, wound closure, and consistent safety and efficacy.

• LUT014: Lutris Pharma 

LUT014 is a lead compound, being developed for the treatment of radiation-induced dermatitis in breast cancer patients. It is a novel B-Raf inhibitor that is applied topically on the skin. The technology is based on harnessing the paradoxical effect of B-Raf Inhibitors on wild-type epithelial cells thus overriding MAP Kinase pathway inhibition.

Top-line results in Phase I/II showed that 75% of patients in Part 1 experienced complete resolution of radiation dermatitis, while Part 2 data showed a clinically relevant treatment effect in 100% of patients treated with LUT014.

 Note: Detailed emerging therapies assessment will be provided in the final report.

Radiation Dermatitis Drugs Market Insights

• Steroids: Topical corticosteroids are commonly prescribed for RID because of their ability to counteract the radiation-induced release of cytokines. While the efficacy of this therapeutic strategy is established in breast cancer and head and neck cancer, the use of topical corticosteroids is frequently associated with the onset of clinically relevant adverse events. In particular, the prolonged use of steroids leads to skin thinning, which may be particularly contraindicated in this condition.
• Silicone-based agents: A moist environment encourages migration of keratinocytes in the wound bed to help promote healing. Silicone-based barrier-forming products have been used for the management of radiation dermatitis. The silicone based film dressing provides mechanical protection from skin damage and TEWL, and may prevent moist desquamation and reduce the severity of radiation dermatitis. Despite these advantages, this silicone-based film dressing may have limitations, such as small bolus effects, easy detachment particularly when bathing or perspiring, and the need for frequent replacement at least twice a week.

Radiation Dermatitis Market Outlook

At present, there is no standard treatment for radiation-induced dermatitis, and a more rational approach to the therapy of this condition has been advocated. The use of new radiation techniques such as breast intensity-modulated radiation therapy seems to reduce the incidence of dermatitis in patients with breast cancer who underwent adjuvant radiotherapy. Emollient creams are widely used for the prevention and treatment of low-grade acute dermatitis. Various studies analyzed the role of topical therapy for the prevention and treatment of radiation-induced dermatitis comparing different emollient creams, but failed to demonstrate the superiority of one over another.

Silicone-based agents in vitro have been shown to regulate fibrosis and wound healing, although with potential practical inconvenience due to non-perfect adherence to the skin when bathing and in men with facial hair. StrataXRT, a silicone-based film-forming agent, was shown to be effective in delaying the development of skin toxicity.

There are several promising emerging pipeline therapies that are expected to fuel the market during the forecast period (2024–2034). Key Radiation Dermatitis Companies such as Amryt Pharma, Xequel Bio, Lutris Pharma, and others, are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the prevention and treatment of radiation dermatitis.

Key Findings

• The US accounted for the largest Radiation Dermatitis Treatment Market Size among the 7MM countries in 2023. The anticipated launch of targeted emerging therapies would bring about changes in treatment methodologies and facilitate market growth.
• Film-forming wound dressing gels are revolutionizing the market by decreasing downtime and promoting rapid re-epithelialization.
• Companies are shifting their focus towards prevention of radiation dermatitis, as the strategies to prevent or mitigate radiation dermatitis are aimed at improving comfort during radiation dermatitis, reducing the degree of inflammation, and promoting healing of skin areas with more severe dermatitis.

Radiation Dermatitis Drugs Uptake

This section focuses on the uptake rate of potential Radiation Dermatitis drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key Radiation Dermatitis Companies evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Radiation Dermatitis Pipeline Development Activities

The Radiation Dermatitis therapeutics market report provides insights into therapeutic candidates in IND and Phase I. It also analyses key Radiation Dermatitis Companies involved in developing targeted therapeutics. 

Pipeline Development Activities

The Radiation Dermatitis therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for radiation dermatitis emerging therapies. 

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Radiation Dermatitis Treatment Drugs

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Ophthalmologists, Professors, and others.

DelveInsight’s analysts connected with 40+ KOLs to gather insights; however, interviews were conducted with 18+ KOLs in the 7MM. Centers such as the Yale School of Medicine, John Mendelsohn Faculty Center, Sidney Kimmel Medical College, the School of the Johns Hopkins University Wilmer Eye Institute, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or radiation dermatitis market trends. 

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. In conjoint analysis, the analyst analyses multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

Radiation Dermatitis Therapeutics Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The Radiation Dermatitis Therapeutics Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Radiation Dermatitis Therapeutics Market Report Scope

• The Radiation Dermatitis Therapeutics Market Report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current Radiation Dermatitis Treatment Market Landscape.
• A detailed review of the radiation dermatitis therapeutics market, historical and forecasted Radiation Dermatitis treatmetn market size, Radiation Dermatitis drugs market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Radiation Dermatitis Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM radiation dermatitis drugs Market.

Radiation Dermatitis Therapeutics Market Report Insights

• Patient Population
• Therapeutic Approaches
• Radiation Dermatitis Pipeline Drugs Analysis
• Radiation Dermatitis Market Size and Trends
• Existing and future Radiation Dermatitis Drugs Market Opportunity 

Radiation Dermatitis Therapeutics Market Report Key Strengths

• 11 Years Radiation Dermatitis Market Forecast
• The 7MM Coverage 
• Radiation Dermatitis Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Radiation Dermatitis Market Forecast Assumptions

Radiation Dermatitis Therapeutics Market Report Assessment

• Current Radiation Dermatitis Treatment Market Practices
• Radiation Dermatitis Unmet Needs
• Radiation Dermatitis Pipeline Drugs Analyais Profiles
• Radiation Dermatitis Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted radiation dermatitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What was the radiation dermatitis total market size, the market size by therapies, and market share (%) distribution in 2023, and what would it look like in 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

• What are the current and emerging options for treating radiation dermatitis? 

• How many companies are developing therapies to treat radiation dermatitis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• How preventive therapies can change the treatment landscape of radiation dermatitis? 

Reasons to Buy

• The Radiation Dermatitis Therapeutics Market Report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving radiation dermatitis.
• Insights on patient burden/disease Radiation Dermatitis Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Radiation Dermatitis Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the Radiation Dermatitis Drugs Market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Radiation Dermatitis Market: Infographics
• Latest DelveInsight Blogs